EdiGene to Unveil Promising Preclinical POC Data for LEAPERâ„¢ 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation
BEIJING--(BUSINESS WIRE)--EdiGene, Inc., a clinical-stage biotechnology company focused on developing transformative gene-editing therapies, announced an oral presentation on the preclinical...




















